Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
INCY
STRONG BUYIncyte Corporation · Healthcare · United States · $22.7B · Avg Vol: $248M/d
COMPANY DESCRIPTION
Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics, primarily in oncology and inflammation/autoimmunity. The company possesses a robust pipeline of innovative small-molecule drugs and a flagship product, Jakafi, which holds a leading market position in myelofibrosis and polycythemia vera. It is a leading biopharmaceutical innovator, recognized for its contributions to oncology and inflammatory disease treatments.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.4B | 3.7B | 4.2B | 5.1B | 14.8% | 5.4B | 5.6B | 6.2B | 10.0% |
| EPS | 1.53 | 2.67 | 0.16 | 6.59 | 62.7% | 7.16 | 7.51 | 8.96 | 16.6% |
| Shares | 222.7M | 224.3M | 193.4M | 198.5M | -10.9% | 199.8M | — | — | — |
| Debt | 41.5M | 38.3M | 43.5M | 40.4M | -0.8% | 39.4M | — | — | — |
| Equity | 4.4B | 5.2B | 3.4B | 5.2B | 5.7% | — | — | — | — |
| Op CF | 969.9M | 496.5M | 335.3M | 1.4B | 13.4% | 1.5B | — | — | — |
| Inv CF | -78.5M | -207.7M | 157.5M | -102.6M | — | — | — | — | — |
| Fin CF | -0.8M | -20.0M | -2.0B | 101.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of INCY are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| INCY | Incyte Corporation(you) | $22.7B | 98 | STRONG BUY |
| EXEL | Exelixis, Inc. | $13.8B | 97 | STRONG BUY |
| 0K6R.L | Neurocrine Biosciences, Inc. | $16.9B | 81 | STRONG BUY |
| HALO | Halozyme Therapeutics, Inc. | $8.9B | 90 | STRONG BUY |
| 0JSY.L | Labcorp Holdings Inc. | $34.9B | 79 | BUY |
| KRYS | Krystal Biotech, Inc. | $11.0B | 84 | STRONG BUY |
| 0J8Z.L | Illumina, Inc. | $24.7B | 69 | BUY |
| RPRX | Royalty Pharma plc | $32.4B | 73 | BUY |
| TGTX | TG Therapeutics, Inc. | $8.5B | 83 | STRONG BUY |
| CPRX | Catalyst Pharmaceuticals, Inc. | $3.9B | 99 | STRONG BUY |
Peer medians: ROE -21.7% · P/E 27.1x · Gross margin 44.3%